Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02185690
Title A Phase I/Ib Study of MEK162, a MEK Inhibitor, in Combination With Carboplatin and Pemetrexed in Patients With Non-squamous Carcinoma of the Lung
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors University Health Network, Toronto, Novartis
Indications

lung large cell carcinoma

lung adenocarcinoma

Therapies

Binimetinib + Carboplatin + Pemetrexed Disodium

Age Groups: adult | senior
Covered Countries CAN

Facility Status City State Zip Country Details
Cross Cancer Institute Edmonton Alberta T6G1Z2 Canada Details
Juravinski Cancer Centre Hamilton Ontario L8V 5C2 Canada Details
The Ottawa Hospital Regional Cancer Centre Ottawa Ontario K1G 3Y9 Canada Details
Princess Margaret Cancer Centre Toronto Ontario M5G2M9 Canada Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field